Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1820 (LINC01820) is a member of the long intergenic non-coding RNA (lincRNA) class, defined as autonomously transcribed non-coding RNAs longer than 200 nucleotides that do not overlap with annotated protein-coding genes[1][3]. LincRNAs generally function in the regulation of gene expression at multiple levels, including chromatin remodeling, genome architecture, RNA stabilization, and transcriptional control[1]. Many lincRNAs display tissue specificity and may act locally on neighboring genes or at a distance through nuclear organization[1]. While the broad class of lincRNAs has been implicated in biological processes such as enhancer activity, gene silencing, and chromatin looping, the precise function and clinical significance of LINC01820 itself remains uncharacterized in the scientific literature as of this writing[1][3]. There are no known disease associations, biomarkers, or relevant therapeutic drugs for LINC01820, and it is not considered a validated therapeutic target at this time.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1820 (LINC01820).